Understanding Hepatitis B Virus Characteristics and Resistance
Official title: Molecular Characteristics of Hepatitis B Virus Integration, Mutation, and Drug Resistance
Run by Beijing Friendship Hospital · NCT06779864 · Data updated 2026-11-12
This study looks at people with chronic hepatitis B to see how the virus behaves and if it has any resistance to treatments, by comparing those on medication to those not receiving treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | Beijing Friendship Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | February 1, 2024 |
| Main results expected | December 30, 2025 |
| Study ends | November 30, 2026 |
| Registry record updated | January 17, 2025 |
| Trial ID | NCT06779864 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with a confirmed diagnosis of chronic hepatitis B who have complete clinical data and retained blood or liver tissue samples.
✕Probably not a fit
Patients without available blood or liver tissue samples will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on patients diagnosed with chronic hepatitis B (CHB) to analyze the molecular characteristics of the hepatitis B virus (HBV), including its integration, mutations, and drug resistance. Participants will be divided into two cohorts: one receiving antiviral treatment and monitored for HBV-related complications, and another assessed at a single time point without treatment. Blood and liver tissue samples will be collected to investigate HBV genotypes and their association with clinical outcomes. The goal is to enhance understanding of HBV's behavior and resistance patterns in different patient populations.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for chronic hepatitis B and better treatment outcomes for patients.
How similar studies have gone: While there have been studies on HBV characteristics, this specific approach focusing on integration and drug resistance is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with hepatitis B surface antigen positive. * Patients who have complete demographic information, clinical data and retained blood samples or liver tissue samples Exclusion Criteria: * Subject who without blood samples or liver tissue samples
Where it's running
-
Beijing Friendship Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Xiaoning Wu
- Email: byfriendship145@163.com
- Phone: 86+(010)6313-8665
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Impact of functional cure on patient-reported outcomes in chronic hepatitis B
This study tests whether people with chronic hepatitis B who achieve a functional cure have better patient-reported outcomes compared to those not cured, relapse, or healthy controls.
-
Sequential combination therapy for functional cure of chronic hepatitis B
This trial tests a new two-drug approach to see if adding immunotherapy to ongoing HBV treatment can lead to loss of hepatitis B surface antigen in adults with chronic hepatitis B.
-
Combination therapy for functional cure in chronic hepatitis B
This phase 2 trial tests whether a sequence of anti-PD-1/PD-L1 antibodies with pegylated interferon and nucleos(t)ide analogues can achieve functional cure (HBsAg loss) in adults with chronic hepatitis B.
-
GST-HG131/GST-HG141 tablets vs placebo in chronic hepatitis B
A phase IIa trial tests GST-HG131 and GST-HG141 tablets against placebo to see if they are safe and help people with chronic hepatitis B.
-
AHB-137 injection in people with chronic hepatitis B
This study tests AHB-137 vs placebo in adults with chronic hepatitis B who have not yet received antiviral treatment.
-
AHB-137 injection pharmacokinetics and safety in people with mild to moderate liver dysfunction and normal liver function
This study tests how AHB-137 behaves in the body and its safety in adults with chronic hepatitis B who have mild to moderate liver problems or normal liver function.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.